Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg starts coverage of Just Group at 'buy', highlights attractive business model

(Sharecast News) - Berenberg initiated coverage of Just Group on Tuesday with a 'buy' rating and 209p price target. It noted that Just Group - which sells annuities in the UK - creates value by investing around 45% of new annuity funds in illiquid assets.

Just Group's main target metric is tangible net asset value (TNAV) the sum of tangible shareholders equity and the contractual service margin (CSM) net of tax, it said.

"The TNAV compound annual growth rate was 16% over 2022-24, Just Group targets a greater than 12% return on equity, which is the main driver of TNAV growth, and we forecast a 13% TNAV CAGR 2024-28E, which is an attractive and sustainable growth rate in our view," Berenberg said.

The bank also highlighted an "attractive" business model. It said Just Group differentiates itself from other life insurance providers in three ways.

"It is very focused as it only sells one product - annuities, in one country - the UK. It is innovative and runs a pricing tool (Beacon) on which it has pre-loaded more than 350 DB schemes; this helps accelerate sales to smaller schemes.

"It invests 45% of the funds for new annuities into illiquid credits, which means it can earn a circa 200 basis points spread over the risk-free rate on the funds invested, while offering policyholders an attractive circa 30bp spread over the risk-free rate."

At 1225 BST, the shares were up 1.6% at 130.60p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.